Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients

D. Jenkins; L. DiFrancesco; A. Chaudhry; D. Morris; S. Glück; A. Jones; R. Woodman; C. B. Brown; J. Russell; D. A. Stewart

doi:10.1038/sj.bmt.1703603

Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients

D. Jenkins, L. DiFrancesco, A. Chaudhry, D. Morris, S. Glück, A. Jones, R. Woodman, C. B. Brown, J. Russell, D. A. Stewart

Braman/Sylvester Comprehensive Cancer Center

Research output: Contribution to journal › Article

15 Scopus citations

Abstract

We report three cases of post-transplant lymphoproliferative disorder (PTLD) in the context of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin's lymphoma. The first two cases received ASCT for MM, one with a CD34-selected autograft and the other with an unmanipulated autograft. Both these cases of PTLD achieved a complete response following treatment with IVIG, gancyclovir, solumedrol and interferon (IFN). The third case received ASCT with an unmanipulated autograft for relapsed angioimmunoblastic lymphoma. He also achieved a complete response but only after rituximab was added to IVIG, gancyclovir, solumedrol and IFN. None of these patients experienced a relapse of their PTLD with follow-up ranging from 1.5 to 5 years. These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT. They also demonstrate the possibility of durable complete remission of post-ASCT PTLD following antiviral and immune modulating therapy.

Original language	English (US)
Pages (from-to)	321-326
Number of pages	6
Journal	Bone Marrow Transplantation
Volume	30
Issue number	5
DOIs	https://doi.org/10.1038/sj.bmt.1703603
State	Published - Sep 1 2002

Keywords

Autologous stem cell transplantation
Epstein-Barr virus
Gancyclovir
Interferon
Post-transplant lymphoproliferative disorder
Rituximab

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1703603

Fingerprint Dive into the research topics of 'Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients'. Together they form a unique fingerprint.

Cite this

Jenkins, D., DiFrancesco, L., Chaudhry, A., Morris, D., Glück, S., Jones, A., Woodman, R., Brown, C. B., Russell, J., & Stewart, D. A. (2002). Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplantation, 30(5), 321-326. https://doi.org/10.1038/sj.bmt.1703603

Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. / Jenkins, D.; DiFrancesco, L.; Chaudhry, A.; Morris, D.; Glück, S.; Jones, A.; Woodman, R.; Brown, C. B.; Russell, J.; Stewart, D. A.

In: Bone Marrow Transplantation, Vol. 30, No. 5, 01.09.2002, p. 321-326.

Research output: Contribution to journal › Article

@article{212db7b18abd482aa7246790a4196e44,

title = "Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients",

abstract = "We report three cases of post-transplant lymphoproliferative disorder (PTLD) in the context of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin's lymphoma. The first two cases received ASCT for MM, one with a CD34-selected autograft and the other with an unmanipulated autograft. Both these cases of PTLD achieved a complete response following treatment with IVIG, gancyclovir, solumedrol and interferon (IFN). The third case received ASCT with an unmanipulated autograft for relapsed angioimmunoblastic lymphoma. He also achieved a complete response but only after rituximab was added to IVIG, gancyclovir, solumedrol and IFN. None of these patients experienced a relapse of their PTLD with follow-up ranging from 1.5 to 5 years. These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT. They also demonstrate the possibility of durable complete remission of post-ASCT PTLD following antiviral and immune modulating therapy.",

keywords = "Autologous stem cell transplantation, Epstein-Barr virus, Gancyclovir, Interferon, Post-transplant lymphoproliferative disorder, Rituximab",

author = "D. Jenkins and L. DiFrancesco and A. Chaudhry and D. Morris and S. Gl{\"u}ck and A. Jones and R. Woodman and Brown, {C. B.} and J. Russell and Stewart, {D. A.}",

year = "2002",

month = sep,

day = "1",

doi = "10.1038/sj.bmt.1703603",

language = "English (US)",

volume = "30",

pages = "321--326",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients

AU - Jenkins, D.

AU - DiFrancesco, L.

AU - Chaudhry, A.

AU - Morris, D.

AU - Glück, S.

AU - Jones, A.

AU - Woodman, R.

AU - Brown, C. B.

AU - Russell, J.

AU - Stewart, D. A.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - We report three cases of post-transplant lymphoproliferative disorder (PTLD) in the context of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin's lymphoma. The first two cases received ASCT for MM, one with a CD34-selected autograft and the other with an unmanipulated autograft. Both these cases of PTLD achieved a complete response following treatment with IVIG, gancyclovir, solumedrol and interferon (IFN). The third case received ASCT with an unmanipulated autograft for relapsed angioimmunoblastic lymphoma. He also achieved a complete response but only after rituximab was added to IVIG, gancyclovir, solumedrol and IFN. None of these patients experienced a relapse of their PTLD with follow-up ranging from 1.5 to 5 years. These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT. They also demonstrate the possibility of durable complete remission of post-ASCT PTLD following antiviral and immune modulating therapy.

AB - We report three cases of post-transplant lymphoproliferative disorder (PTLD) in the context of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin's lymphoma. The first two cases received ASCT for MM, one with a CD34-selected autograft and the other with an unmanipulated autograft. Both these cases of PTLD achieved a complete response following treatment with IVIG, gancyclovir, solumedrol and interferon (IFN). The third case received ASCT with an unmanipulated autograft for relapsed angioimmunoblastic lymphoma. He also achieved a complete response but only after rituximab was added to IVIG, gancyclovir, solumedrol and IFN. None of these patients experienced a relapse of their PTLD with follow-up ranging from 1.5 to 5 years. These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT. They also demonstrate the possibility of durable complete remission of post-ASCT PTLD following antiviral and immune modulating therapy.

KW - Autologous stem cell transplantation

KW - Epstein-Barr virus

KW - Gancyclovir

KW - Interferon

KW - Post-transplant lymphoproliferative disorder

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0036737757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036737757&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703603

DO - 10.1038/sj.bmt.1703603

M3 - Article

C2 - 12209355

AN - SCOPUS:0036737757

VL - 30

SP - 321

EP - 326

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -